Tech Company Financing Transactions
Diagonal Therapeutics Funding Round
On 1/9/2026, Diagonal Therapeutics raised $125 million in Series B investment from Janus Henderson Investors, Sanofi Ventures and Atlas Venture.
Transaction Overview
Company Name
Announced On
1/9/2026
Transaction Type
Venture Equity
Amount
$125,000,000
Round
Series B
Investors
Janus Henderson Investors (Lead Investor)
Sanofi Ventures (Lead Investor)
Proceeds Purpose
The company intends to sue the funds to support advancement of DIAG723, a first-in-class, disease-modifying clustering antibody designed to correct the underlying cause of hereditary hemorrhagic telangiectasia (HHT) and pulmonary arterial hypertension (PAH).
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
300 Technology Square, 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
At Diagonal Therapeutics, we have assembled a team of scientific and business leaders with extensive experience in building companies and developing innovative antibody therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Lugovskoy
Chief Scientific Officer
Patrick Andre
Vice President
Melissa Geddie
VP - Bus. Development
Sandra Teixeiraq
VP - Finance
Eric Duhaime
Browse more venture capital transactions:
Prev: 1/9/2026: Canopy venture capital transaction
Next: 1/9/2026: BlueNalu venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs